Contact: Sam Zamarripa
Intent Solutions™
Phone: 404-229-3804


ATLANTA (August 30, 2017) – Intent Solutions™, creator of the breakthrough medical device technology tad™, is excited to announce the addition of its new Chief Strategy Officer, Paul Quiner. Paul has spent his career in healthcare both from product and service perspectives. “Paul brings extensive experience in business including strategy, mergers and acquisitions experience,” said Sam Zamarripa, CEO. “In addition we believe that Paul’s legal training will give him a unique perspective on our regulatory issues at both the state and federal level.”


“To be a part of Intent Solutions at this stage in the development was especially intriguing to me,” Paul explains. “Intent Solutions’ laser focus is on a critical aspect of healthcare: the ability to ensure the right dose was dispensed to the right patient at the right time. This is powerful, and can have a positive impact on healthcare outcomes as well as clinical research.”

As Chief Strategy Officer and General Counsel, Quiner will focus on Intent Solution’s overall strategy, ensuring all activities are aligned with Intent Solution’s vision, mission, core values and strategic priorities. In addition, Paul will play a central role along with CEO Sam Zamarripa in the day to day management of the company’s goals and objectives.

Paul holds a B.S. in Finance and a J.D. from the University of Wyoming, Laramie, Wyoming.

tad™, for “Take As Directed”™ is a smart, mobile, medication dispenser that helps patients obtain better health outcomes by helping the right patient take the right dose at the right time.

About Intent Solutions, Inc.

Headquartered in Atlanta, Georgia, Intent Solutions is a technology-enabled services company with hardware and software for monitoring and managing medication adherence in pharmaceutical research trials and in several market verticals of applied healthcare.

It is estimated that up to one-half of all prescriptions are not taken which results in deaths of over 125,000 from adherence related causes and a staggering economic burden in health care of $300B, and a global revenue loss of $564B to pharmaceutical companies. The adherence problem may include taking more or less than prescribed, skipping doses, and also the abuse, misuse, and diversion of medications.